PD-L1 Expression Level Displays a Positive Correlation with Immune Response in Pancreatic Cancer

Table 1

Correlations among PD-L1 expression, FOXP3⁺ Treg infiltration, and clinicopathologic characteristics of pancreatic cancer patients.

PD-L1 expression					FOXP3^+ Treg infiltration
Clinicopathological parameters	Negative; (%)	Positive; (%)			Negative; (%)	Positive; (%)
No. of patients	37 (58.7)	26 (41.3)			28 (44.4)	35 (55.6)
Age (years)
<65	14 (51.6)	13 (48.1)	-0.121	0.345	13 (48.1)	14 (51.9)	0.065	0.615
≥65	23 (63.9)	13 (36.1)			15 (41.9)	21 (58.3)
Gender
Female	13 (59.1)	9 (40.9)	0.005	0.967	10 (45.5)	12 (54.5)	0.015	0.908
Male	24 (58.5)	17 (41.5)			18 (43.9)	23 (56.1)
Tumor status
T1	5 (100)	0 (0)	0.472	<0.001	4 (80)	1 (20)	0.277	0.028
T2	14 (87.5)	2 (12.5)			9 (56.3)	7 (43.7)
T3	18 (43.9)	23 (56.1)			15 (36.6)	26 (63.4)
T4	0 (0)	1 (100)			0 (0)	1 (100)
Nodal status
N0	21 (80.8)	5 (19.2)	0.375	0.002	19 (73.1)	7 (26.9)	0.483	<0.001
N1	16 (43.2)	21 (56.8)			9 (56.8)	28 (56.8)
Metastatic status
M0	36 (66.7)	18 (33.3)	0.395	0.001	27 (50)	27 (50)	0.274	0.03
M1	1 (11.1)	8 (88.9)			1 (11.1)	8 (88.9)
Pathologic status
Stage I	8 (88.9)	1 (11.1)	0.556	<0.001	7 (77.8)	2 (22.2)	0.542	<0.001
Stage IIa	19 (82.6)	4 (17.4)			16 (69.6)	7 (30.4)
Stage IIb	9 (42.9)	12 (57.1)			4 (19)	17 (81)
Stage III	0 (0)	1 (100)			0 (0)	1 (100)
Stage IV	1 (11.1)	8 (88.9)			1 (11.1)	8 (88.9)
FOXP3^+ Treg infiltration
Low	22 (78.6)	6 (21.4)	0.360	0.004
High	15 (42.9)	20 (57.1)